In light of the fact that the ODT market is growin

In light of the fact that the ODT market is growing significantly, driven by patient demand, rapid melt technology, provides pharmaceutical companies with the much-needed opportunity for product line extensions for a wide variety of drugs. ScripsAmerica sees a significant opportunity as a contract developer of Quickmelt technology embedded in RapiMed specialty pharmaceuticals. In March 2010, ScripsAmerica entered into a product development, manufacturing, and supply agreement for Acetaminophen 80mg and 160mg orally disintegrating rapid dissolve tablets under which its partner will develop and supply the product, while ScripsAmerica will fund all development costs and own the final product. The Company’s initial focus is on Pediatric analgesic 80mg and 160mg orally disintegrating rapid dissolve tablets, which are under development with a market rollout scheduled for Q2 2013. The 80mg and 160mg dosing strength will be particularly applicable to children to solvecommon overdosing or under dosing issues that 2-11-year-olds tend to experience when taking liquid pain relievers or fever reducers in doses intended for adults. Safely administering liquids such as Children’s Tylenol Suspension to children requires precise dosage measurement in increments of half a teaspoon, depending on the child’s weight or age. Inadvertent overdosing – whether by an adult’s error or perhaps a child’s self-administration - may lead to severe liver damage and requires immediate medical attention even in the absence of signs or symptoms. Conversely, ODTs such as ScripsAmerica’s Pediatric RapiMed represent a precise, standardized dose in the form of discrete, easy-to-count, individually blister-packaged tablets, thereby reducing the probability of human error while the drug is being administered. Finally, the taste of ODTs can easily be tailored to appeal to children, using a variety of flavored coatings. ScripsAmerica’s Pediatric “RapiMed” will compete with other children’s analgesic products, such as J&J’s Children’s Tylenol Suspension Liquid and Children’s Tylenol Meltaways, Novartis’ Triaminic Fever Reducer Pain Reliever, and Perrigo’s Junior Strength Non-Aspirin Suspension Liquids & Drugs. According to Euromonitor International’s research, J&J’s Children’s Tylenol sales represented 23% of global and 76% of U.S. retail value sales in child-specific analgesics. Global sales were valued at $695 million in 2009. ScripsAmerica anticipates project completion with market rollout scheduled for 2014. RapiMed formulation is compatible for use in the development of Oral Delivery Technology products to treat Migraines, Sleep Deprivation, Allergies, and Vitamin Deficiencies